AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03436160 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WR909390
Description: 100 mcg Carbon-14 radio labeled WR909309 at an exposure no greater than 250 nCi per dose, administered both IV (bolus) and PO with a six half-life wash-out period between IV and PO administration. Interim analyses will be done at Day 14 following the IV dosing groups in order to assess half-lives of the three compounds to ensure the wash-out period between IV and PO dosing is at least six half-lives long.
Study NCT01607385 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GSK2330672
Description: BID, repeat doses
Study NCT01607385 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: BID, repeat doses
Study NCT01607385 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GSK1614235
Description: BID, co-dosed BID with last dosing day of active/placebo repeat doses
Study NCT01607385 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: GSK1614235
Description: BID, co-dosed BID with last dosing day of active/placebo repeat doses
Study NCT01168063 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Molecular detection of antibiotic resistance
Description: Helico DR®, triple therapy (Proton Pomp Inhibitor (PPI), amoxicillin, clarithromycin, metronidazole)
Study NCT01168063 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: standard triple therapy (PPI, amoxicillin, clarithromycin, metronidazole)
Description: 2 lines of treatments :~1) PPI + Amoxicillin + Clarithromycin for 7 days~1) PPI + Amoxicillin + Metronidazole for 14 days
Study NCT02715895 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Friso
Description: Friso formula feeding on demand for 3 months
Study NCT02715895 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Wyeth
Description: Wyeth formula feeding on demand for 3 months
Study NCT02715895 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Breast milk
Description: Breast milk feeding on demand
Study NCT03005093 — intervention group
Intervention type: OTHER
Intervention: CAREGIVERS
Description: The Turkish Feeding/Swallowing Impact Survey will be completed by the caregivers
Study NCT02056600 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemigliptin/metformin HCl sustained release
Description: Administration of combination of gemigliptin 50mg/metformin HCl sustained release 1000mg, for 1day.
Study NCT03005093 — intervention group
Intervention type: OTHER
Intervention: CHILDREN OF CAREGIVERS
Description: Chewing performance with Karaduman Chewing Performance Scale, tongue control with Tongue Thrust Rating Scale, dysphagia symptom severity with the Pediatric version of the Eating Assessment Tool will be evaluated. These assessments will be done before and after swallowing rehabilitation program.
Study NCT03623880 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Unified Protocol
Description: The unified protocol is a form of cognitive behavior therapy focused on helping the person reduce emotional distress through cognitive changes and behavioral skills. Exercises included confronting emotional-driven behaviors and mindfulness activities.
Study NCT03623880 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Supportive Therapy
Description: Supportive therapy seeks to improve self-esteem, aid the patient with problem solving, and provide structured support using empathetic listening.
Study NCT02978989 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: nonsolo LC
Description: This patient is scheduled to undergo nonsolo laparoscpic cholecystectomy.
Study NCT03809377 — intervention group
Intervention type: PROCEDURE
Intervention: Blood donation during radiotherapy
Description: Participants will be asked to donate a blood sample at 5 time points during and after radiotherapy
Study NCT04316039 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Concurrent chemotherapy is to receive oral temozolomide, 75 mg/m2 per day, during radiation therapy. Adjuvant chemotherapy will be treated with six cycles of temozolomide, 150 to 200 mg/m2 per day for five consecutive days, repeated every 4 weeks. There is a 28-day break during radiotherapy and adjuvant temozolomide.
Study NCT04316039 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: intensity modulated radiation therapy
Description: The radiation dose is 50-54 Gy given in 25-30 fractions (1.8-2.0 Gy once daily, 5 days per week).
Study NCT04316039 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: intensity modulated radiation therapy
Description: The radiation dose is 50-54 Gy given in 25-30 fractions (1.8-2.0 Gy once daily, 5 days per week).
Study NCT04290988 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EEG Neurofeedback
Description: Active EEG neurofeedback
Study NCT04290988 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Feedback
Description: Sham EEG feedback sessions identical to active sessions except that the feedback given to the participant will not be based on the individual's live EEG activity.
Study NCT03754855 — intervention group
Intervention type: BEHAVIORAL
Intervention: Questionnaire
Description: Questionnaire
Study NCT02978989 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: solo LC
Description: This patient is scheduled to undergo solo laparoscpic cholecystectomy.
Study NCT01079143 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Certican®
Description: Certican® was supplied to the participating centers by Novartis for the whole duration of the study in the form of tablets containing 0.75, 0.5 and 0.25 mg and packaged in blister packs.
Study NCT06621992 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Skills to Enhance Positivity
Study NCT06621992 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as Usual
Description: Participants received treatment as usual
Study NCT00334633 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tinidazole, metronidazole
Description: Tinidazole 500 mg bid; Tinidazole 1mg bid; Metronidazole 500mg bid
Study NCT01079143 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Neoral
Description: Neoral® was also supplied to participating centers for the entire duration of the study in the form of soft capsules of 10 mg, 25 mg, 50 mg and 100 mg, and packaged in blister packs.
Study NCT01079143 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Myfortic
Description: Myfortic ® was supplied to the participating centers for the duration of the study in the form of 180 and 360 mg gastro-resistant, film-coated tablets. Myfortic® treatment was provided to patients preoperatively or within 24 hours post-transplantation according to the practices of the center. The starting dose was generally 1,440 mg/day, in 2 daily oral fractions, administered at 12 hour intervals up to randomization. Depending on the practices of the center and for the first 6 weeks post-transplantation, a maximum daily dose of 2160 mg of Myfortic® could be administered. In the Neoral® group, the daily dose of 1440 mg was maintained throughout the study.~In the Certican® group, the dose was halved (i.e. 720 mg/day) on introducing Certican® and maintained at 720 mg/day until the end of the study.~An increase in the daily dose of Myfortic® (in the Certican® group) was not authorized unless this was a temporary increase that did not exceed a period of 14 consecutive days.
Study NCT01079143 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Myfortic
Description: Myfortic ® was supplied to the participating centers for the duration of the study in the form of 180 and 360 mg gastro-resistant, film-coated tablets. Myfortic® treatment was provided to patients preoperatively or within 24 hours post-transplantation according to the practices of the center. The starting dose was generally 1,440 mg/day, in 2 daily oral fractions, administered at 12 hour intervals up to randomization. Depending on the practices of the center and for the first 6 weeks post-transplantation, a maximum daily dose of 2160 mg of Myfortic® could be administered. In the Neoral® group, the daily dose of 1440 mg was maintained throughout the study.~In the Certican® group, the dose was halved (i.e. 720 mg/day) on introducing Certican® and maintained at 720 mg/day until the end of the study.~An increase in the daily dose of Myfortic® (in the Certican® group) was not authorized unless this was a temporary increase that did not exceed a period of 14 consecutive days.
Study NCT01079143 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simulect®
Description: The administration of Simulect® was part of the standard immunosuppressant therapy. This induction therapy was provided to patients in the form of commercial ampoules each containing 20 mg. Simulect® was administered to each patient at the dose of 20 mg on D0 and D4 post-transplantation.
Study NCT01079143 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Simulect®
Description: The administration of Simulect® was part of the standard immunosuppressant therapy. This induction therapy was provided to patients in the form of commercial ampoules each containing 20 mg. Simulect® was administered to each patient at the dose of 20 mg on D0 and D4 post-transplantation.
Study NCT01842399 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Resveratrol
Description: Nutriceutical
Study NCT01842399 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2x/day orally
Study NCT01145859 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban (Xarelto, BAY59-7939)
Description: Weight adjusted dose with equivalent exposure compared to 10 mg or 20 mg doses in adults
Study NCT01079143 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Corticosteroids
Description: An intravenous steroid treatment could be administered peri or intraoperatively according to local practice at each center. Oral steroid treatment was quickly introduced (in the week following transplantation) at a daily dose of 20 mg and was then reduced and continued throughout the study at a minimum dose of 5 mg/day.
Study NCT01079143 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Corticosteroids
Description: An intravenous steroid treatment could be administered peri or intraoperatively according to local practice at each center. Oral steroid treatment was quickly introduced (in the week following transplantation) at a daily dose of 20 mg and was then reduced and continued throughout the study at a minimum dose of 5 mg/day.
Study NCT01360567 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Green tea extract
Description: 500 mg . one capsule of green tea extract, 3 times per day
Study NCT01360567 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 500 mg . one capsule of placebo, 3 times per day
Study NCT04887181 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Teethmate Desensitizer
Description: Powder and liquid contained in the material were mixed. It was applied to the buccal surface of the sensitive tooth. then it was washed away from the tooth surface. 1-4 sessions were applied until the sensitivity disappeared.
Study NCT04887181 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Gluma Desensitizer
Description: The material was applied to the buccal surface of the tooth with sensitivity. It was washed with water and removed from the tooth surface. 1-4 sessions were applied until the sensitivity disappeared.
Study NCT04887181 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hybrid Bond
Description: It was applied to the buccal surface of the sensitive tooth with an applicator. It was cured with a LED light device. Dentin sensitivity was checked with evaporative air application. The process was repeated until the sensitivity disappeared.
Study NCT02821832 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Saliva collection
Description: For biomarker assessments
Study NCT02821832 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Saliva collection
Description: For biomarker assessments
Study NCT02821832 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Saliva collection
Description: For biomarker assessments
Study NCT02821832 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Urine collection
Description: For biomarker assessments
Study NCT02821832 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Urine collection
Description: For biomarker assessments
Study NCT02821832 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Urine collection
Description: For biomarker assessments
Study NCT02821832 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Sputum collection
Description: For primary endpoint assessments and other biomarker assessments
Study NCT02821832 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sputum collection
Description: For primary endpoint assessments and other biomarker assessments
Study NCT02821832 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sputum collection
Description: For primary endpoint assessments and other biomarker assessments
Study NCT02821832 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Blood Collection
Description: For biomarker and eligibility assessments
Study NCT02821832 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Blood Collection
Description: For biomarker and eligibility assessments
Study NCT02821832 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood Collection
Description: For biomarker and eligibility assessments
Study NCT02821832 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: PET/CT Scan
Description: Imaging of the lungs to establish disease extent and severity
Study NCT02821832 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: PET/CT Scan
Description: Imaging of the lungs to establish disease extent and severity
Study NCT02821832 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: PET/CT Scan
Description: Imaging of the lungs to establish disease extent and severity
Study NCT02821832 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Isoniazid, Rifampicin, Pyrazinamide and Ethambutol
Description: Treatment-standard of care
Study NCT02821832 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isoniazid, Rifampicin, Pyrazinamide and Ethambutol
Description: Treatment-standard of care
Study NCT02821832 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isoniazid, Rifampicin, Pyrazinamide and Ethambutol
Description: Treatment-standard of care
Study NCT03086070 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole 20mg
Description: omeprazole 20 mg capsules were administered per os half an hour before breakfast for 8 weeks
Study NCT03086070 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: Matching placebo oral capsules were administered per os half an hour before breakfast for 8 weeks
Study NCT03138616 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vitamin D
Description: take 1600 units of vitamin D daily for nine months
Study NCT03445507 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chat bot
Description: Patients in intervention arm will use an evidence-based chat bot as an aid for smoking cessation
Study NCT03445507 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Usual care given by their usual general practitioners and nurses of primary care health centres, as defined in Public Health System Portfolio.
Study NCT02186015 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cholecalciferol
Description: Enrolled women will receive 50,000 IU weekly supplementation of cholecalciferol for 8 weeks.
Study NCT02584075 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Byetta (Exenatide)
Description: Exenatide treatment: 5 µg twice/day subcutaneous injection for 4 weeks, 10 µg twice/day subcutaneous injection for 8 weeks.
Study NCT02584075 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glucophage ( Metformin Hydrochloride)
Description: Metformin 500mg Tid
Study NCT00744796 — intervention group
Intervention type: PROCEDURE
Intervention: DSAEK
Description: Endothelial Keratoplasty
Study NCT00744796 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Anterior Segment Optical Coherence Topography (OCT)
Description: Non-contact, high resolution, cross sectional imaging of the anterior segment of the eye.
Study NCT00744796 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Best Spectacle Corrected Visual Acuity (BSCVA)
Description: Visual acuity determined using a combination of detecting hand motion, counting fingers displayed and reading Snellen charts at specific distances.
Study NCT03682237 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Carbohydrate counting, automated bolus calculation
Description: Group training in carbohydrate counting and bolus calculation. The app MySugr will be taught and downloaded on own smart phone and person specific parameters will be estimated and entered in the app with the patients. SMBG measures at least 4 times daily with patients own preferred glucose meter.
Study NCT03682237 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Flash glucose monitoring (FGM)
Description: Group training, patients will be instructed to use unblinded FGM for the whole study period. Patients are recommended to measure SMBG according to FGM manufactures guideline and handling of trend arrows etc.
Study NCT00994396 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo soft gel pills (soy bean oil encapsulated in soft gel comprised of gelatin, glycerin and water) twice per day for 6 mos.
Study NCT00994396 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D 3 cholecalciferol
Description: 4000 IU (2 soft gels at 2000 IU each) vitamin D3 per day for 6 months.
Study NCT02581189 — intervention group
Intervention type: DRUG
Intervention: Ombitasvir/paritaprevir/ritonavir
Description: Co-formulated tablet
Study NCT02581189 — intervention group
Intervention type: DRUG
Intervention: Dasabuvir
Description: Tablet
Study NCT02581189 — intervention group
Intervention type: DRUG
Intervention: Ribavirin
Description: Tablet
Study NCT02810483 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topiramate
Description: Increase phase. The starting dose is 50 mg / day with gradual increase in dose to 50 mg / week until the end of the 3rd week.~Dose of study:~200mg for 5 weeks.~Decrease phase:~The 9th week, 100mg for 4 days then 50mg for 3 days.
Study NCT02810483 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator
Description: ncrease phase. The starting dose is 50 mg / day with gradual increase in dose to 50 mg / week until the end of the 3rd week.~Dose of study:~200mg for 5 weeks.~Decrease phase:~The 9th week, 100mg for 4 days then 50mg for 3 days.
Study NCT01960114 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen ER
Description: Single dose (2 tablets) Acetaminophen ER 750 mg
Study NCT01960114 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single dose (2 tablets) Acetaminophen ER 750 mg matching placebo
Study NCT00676975 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Chinese Medicine
Description: A herbal extract 17g once daily for 8 weeks for lower dosage, and 34g for higher dosage.~The 20-herb formulation are Agastache rugosa,Fraxinus rhynchophylla, Angelica dahurica,Glycyrrhiza uralensis, Artemisia capillaris, Magnolia officinalis, Atractylodes macrocephala,Paeonia lactiflora, Aucklandia lappa, Plantago asiatica,Bupleurum chinense, Phellodendron amurense, Citrus reticulate, Poria cocos, Codonopsis pilosula, Saposhnikovia diraricata, Coix lacryma-jobi, Schisandra chinensis, Coptis chinensis, Zingiber officinale
Study NCT01567566 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercise rehabilitation program
Description: 6 week home based exercise rehabilitation program with 6 weekly supervised sessions using real time ultrasound as biofeedback to augment training in both treatment arms
Study NCT00676975 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Traditional Chinese Medicine Placebo
Description: Placebo once daily for 8 weeks
Study NCT03745794 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Best Practice
Description: Given standard of care
Study NCT03745794 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Best Practice
Description: Given standard of care
Study NCT03745794 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Quadratus Lumborum Block
Description: Undergo QL block
Study NCT03745794 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quadratus Lumborum Block
Description: Undergo QL block
Study NCT03745794 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT03745794 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT03745794 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT03745794 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT02954900 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: RealRisks
Description: RealRisks is a web-based patient decision aid with modules that present information about risk assessment and chemoprevention.